Board of Directors
Shawn M. Titcomb
Co-Founder and Chairman
Mr. Titcomb is Co-Founder and Managing Partner of Allele Capital Partners, a life sciences and healthcare IT focused advisory and merchant banking firm. Previously he served as the Head of Investment and Merchant Banking at Noble Life Science Partners, a division of Noble Capital Markets. Prior to Noble, he was a Founding Partner at Variant Research Corporation and Senior Vice President of Avalon Research Group both of which focused on long and short life sciences equity research. Mr. Titcomb is highly proficient in scientific and corporate due diligence with the ability to leverage proprietary relationships with key opinion leaders (KOLs) and C-level life sciences executives. He has a proven track-record of creating and identifying emerging life sciences companies with successful management teams, milestone outcomes and investment returns. In addition to serving as Variant's Chairman, Mr. Titcomb also serves as an Advisor to Palm Beach County's Business Development Board for Life Sciences and as Co-Chair for the Life Sciences Executive Council of South Florida.
Stephen C. Glover
Co-Founder and Chief Executive Officer
Mr. Glover has over 30 years of business experience in biopharmaceuticals and life sciences. Mr. Glover is formally the Co-Founder of Coherus Biosciences where he was focused on the business strategy, partnerships, product development efforts and capitalization of the company. Prior to Coherus, he was the President of Insmed Therapeutic Proteins as well as Chief Business Officer of Insmed Incorporated. At Insmed, Mr. Glover was responsible for the creation of the biosimilar business unit and the divestiture of the business to Merck. As Chief Business Officer he led Insmed's strategic review process which resulted in the merger of Insmed and Transave. Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. At Andrx Mr. Glover was responsible for the strategy and operation of the Andrx Labs which developed and marketed products in metabolic diseases and Men's Health, and Andrx Therapeutics which was focused on the development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health. Mr. Glover has multifaceted experience in Fortune 100, start up and entrepreneurial environments. His transaction experience covers over 25 transactions totaling over $10 billion.
Aaron Greenblatt, Pharm D
Chief Executive Officer, G&W Laboratories, Inc.
Mr. Greenblatt has been the Chief Executive Officer of G&W Laboratories, Inc. since March 12, 2015. Mr. Greenblatt previously served as Chief Commercial Officer and Executive Vice President at G&W Laboratories, Inc. Mr. Greenblatt rotated through several departments in G&W during various summer internships throughout high school and college and joined G&W full-time in 2009 as the head of Supply Chain. After building the newly formed Supply Chain department at G&W, Mr. Greenblatt also ran the packaging department before becoming Director of Sales, Business Development, and Company Culture. Then, as Chief Commercial Officer, Mr. Greenblatt was the architect and chief negotiator of G&W’s first and second acquisitions, tripling its manufacturing footprint and employee base in a twelve month period. Mr. Greenblatt also focused on deepening customer relationships and ensuring that G&W attracts and retains employees who are aligned with its core values.
As the fourth generation CEO from the Greenblatt family, Mr. Greenblatt continues to focus on instilling the core values into the company culture, talent-recruitment and development, commercial partnerships, and new product acquisitions, in order to further increase the company’s growth trajectory, and continue to build a sustainable organization.
Jules A. Müsing
Pharmaceutical Executive & Advisor
In the course of his career in the Pharmaceutical and Biotechnology Industry, mainly at Johnson & Johnson [NYSE: JNJ], Jules A. Müsing has been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology prescription products and technologies and the establishment of corporate strategic alliances.
In this position he negotiated, signed and implemented several multi-million dollar deals with small, medium and large Pharmaceutical and Biotechnology companies on a worldwide basis.
He has more than 40 years’ experience in the pharmaceutical and biotechnology industry, and has been Chief Executive Officer, President and Managing Director of Johnson & Johnson companies in the US and in Europe and of the Swiss-based company Ares Serono in the US. He also has been Executive Vice President of all Ares Serono companies in North- and Latin America.
Additional accomplishments relate to his business development activities in S.E. Asia, where he was instrumental in the establishment of Johnson & Johnson pharmaceutical subsidiaries in Japan, Australia, South Africa, Thailand and other S.E. Asian countries, and to his role of Vice President Marketing International for the Janssen Group of Companies Worldwide.
Mr. Müsing currently serves as a member of the Board of Directors of TherapeuticsMD, Inc. and of Delphi Digital, Inc., and is a member of the Scientific Advisory Board of Noble Financial Capital Markets, an Investment Banking and Merchant Banking boutique in Boca Raton, Florida.
Mr. Müsing previously served as a member of the Board of Directors of Johnson & Johnson companies in Germany, France, Italy and the UK and served as a member of the Management Board of Ortho Biotech, a Johnson & Johnson biotechnology company in the US and in Europe. He also served as Executive Chairman of Pelican Therapeutics, Inc. and as a member of the Board of Directors of iBio, Inc.
Jules A. Müsing received his Postgraduate degree of Master in Sciences from the University of Brussels (Belgium) and his Academic degree in Economic and Financial Sciences - Cum Lauda - from the University of Antwerp (Belgium). He also completed several Postgraduate courses at Harvard University, US and the University of Cambridge, UK. His Honors thesis on the European Monetary Union (1975) was awarded with “ special recognition “ by the Prime Minister of Belgium.
He has been speaker and moderator at several national and international Healthcare conferences and congresses, and is an advisor to a number of Biotechnology and Pharmaceutical companies.
Nico P. Pronk
Mr. Pronk is President and Chief Executive Officer of Noble Capital Markets. Mr. Pronk began his financial career in Europe in 1986 on the European Options Exchange (EOE). Mr. Pronk has over 25 years’ experience working with IPOs, Secondary Offerings, Private Placements and Mergers and Acquisitions. During his career he has served as Director or Advisor to numerous privately-held and publicly traded companies. Mr. Pronk is a graduate of the Netherlands Institute of Banking and Finance, and holds various FINRA licenses. Mr. Pronk is the current Chairman of the Board of Directors of the Dutch Chamber of Commerce in Miami, is a member of the Board of Directors of the YMCA of South Palm Beach County Foundation, and is a member of the Board of Directors of MobileHelp.